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Summary
After the mtroduction of a new pasteunsed factor VIII concentrate
(Factor VIIICPS-P) m The Netherlands rn June 1990, an mcrease m the
occurrence of inhibitois m hemophihaA patients was reported The
clinical course of this gtoup of Inhibitors (n = 12) was compared with
hemophilia patients in whom an Inhibitor developed before June 1990
(classic Inhibitors) (n = 32) Stnkmg differences were found between
both groups not only m patient age (median 22 yeais versus 8 yeais)
and number of exposure days (<50 - >1000 versus <50), äs descnbed in
previous reports, but also m clinical course and response to treatment
In the recent group of mhibitois antibody titers showed a rapid declme
when product was changed which was not the case m the group with
classic Inhibitors In the gioup of classic Inhibitors immune tolerance
therapy with low dose factor VIII succeeded m 83% Success was to a
high degree dependent on the mhibitor level In the gioup of recent
mhibitors immune tolerance with the same concentiate was only
successful m a smgle patient However, once the patients were switched
to anothei concentrate, antibody levels diopped to less than 2 BU/ml
withm 8 months m all patients
It seems hkely that m this group of product associated mhibitors,
treatment success was due to elimmation of antigen Stimulation rather
than mductton of immune tolerance
Introduction
The development of antibodies to factor VIII (mhibitors) is a senous
comphcation m hemophilia treatment It is estimated that about 5-25%
of hemophilia patients develop mhibitors (1-8) In severe hemophilia
inhibitois usually develop at an early age and are seldom found after 50
days of exposure to factor VIII clottmg products (7) In older patients
mhibitor development is raie and usually without clinical problems
In 1991 a sudden mcrease in the development of mhibitors was seen
m The Netherlands and Belgmm (9, 10) This mcrease was shown to
be associated with one particular factor VIII pioduct This pasteunsed
mtermediate punfied factor concentrate (factor VIII CPS-P) was
mtroduced m 1990 by the Central Laboratory of The Netherlands Red
Cross Blood Transfusion Service (CLB) Inhibitors weie subsequently
detected m 12Dutch patients with hemophihaA, which imphed a
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5-fold mcreased nsk compared to the time penod pnor to the mtroduc-
tion of this concentrate (9) In this paper we descnbe the clinical
course m the 12 patients who developed an mhibitor after factor VIII
CPS-P admimstration ("recent mhibitors") and compare this to those of
hemophilia patients in whom an mhibitor was detected before the new
product was mtroduced ("classic mhibitors")
Methods
Study Population
The study population consisted of all 32 imbitor patients registered in our
centei between 1966 and June 1990, äs well äs of 12 patients found m the
national study on mhibitor formation m hemophilia patients between June 1990
and March 1992 Togethei they form the majonty (estimated at more than 90%)
of hemophilia patients with a known mhibitor m The Netherlands Inhibitor
patients could be divided mto three groups
Group l Classic Inhibitors
This group consisted of all mhibitor patients detected before June 1990
(n = 32) Nme of these patients (group l a) had not received immune tolerance
therapy, whereas 23 patients (group l b) had received this tieatmenl m a
dosage of 25 U/kg body weight (bw) factor VIII, given 3 times a week 01 on
alternate days (11, 12) For immune tolerance therapy we used cryoprecipitate
and a vanety of concentrates
Group 2 Recent Inhibito: s
Twelve patients m whom an mhibitor was detected after the mtroduction of
factor VIII CPS-P (9) In none of these patients antibodies had been detected
before, 11 of them have severe hemophilia Immune tolerance therapy m this
group of patients varied fiom 25 U/kg bw factor VIII on alternate days, to
25 U/kg bw factor VIII daily
Evaluatwn of Immune Toleiance Therapy
Immune tolerance therapy was consideied to be successful when the
mhibitor level feil to less than 2 BU/ml, with a factor VIII recovery of at least
50% of normal, a factor VIII half life of 6 h or more (13) and the absence of an
anamnestic response of the mhibitor after mfusion with factor VIII
Laboratory Assay
Plasma Samplmg
Plasma samples foi factor VIII and mhibitoi assays were drawn accordmg to
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Fig l Cumulative numbei of hemophiha patients with an mhibitor detected
between 1966 and 1992 m the Netherlands Classic = classic mhibitor detected
between 1966 and June 1990 (group 1) CPS-P mh = recent mhibitors,










Fig 2 Disappearance of factor VIII Inhibitors A Classic mhibitor patients
(n = 5) never treated with factor VIII smce the detection of the mhibitor
B Classic mhibitor patients (n = 27) treated with factor VIII or with immune
tolerance therapy
C Recent mhibitor patients (n = 12) who developed an mhibitor after 1990









































' classic Inhibitors detected between 1966 and 1990 (group 1)
^ recent mhibitors detected after 1990 (group 2)
1 exposure to all factor VIII concentrates
2 exposure to Factor VIII CPS-P
3 IT = Immune tolerance therapy
needle m a sihcone trealed Vacutamei tube m which 0 5 ml of 3 8%
sodiumcitrate was added Immediately after collection samples weie caiefully
mixed and centnfuged at 3000 X Gfor 15 mm at4°C, caiefully pipelted off and
stored in a plastic tube at -20°C
Samples of all patients with classic mhibitors and of 11 recent mhibitoi
palients with severe hemophiha were analysed at the coagulation laboratory
of the Umversity Hospital of Utrecht (head Dr JW Akkerman) Additional
mhibitoi measurements were performed at the local hemophiha centers
Inhibitor As wy
Inhibitor measurements were peiformed usmg the Bethesda method äs
descnbed by Kasper et al (14) In patients with positive mhibitoi tests, blood
samples foi mhibitor measurement weie taken every 4 to 8 weeks
Factor VIIIAssays
These were performed by the one stage method based on the kaolme activa
ted partial thiomboplastme time and expressed äs a percentage of factor VIII
present m pooled normal human plasma (15)
In Vivo Recovery
Blood samples for factor VIII assays were taken befoie and 15 mmutes after
transfusion with factor VIII Recovery was defmed äs the level of factor VIII
measured 15 mm aftei mfusion and the expected level calculated by the method
accordmg to Lee et al (16) Recoveiy was assessed every 4 to 8 weeks m all
mhibitoi patients who were treated with factor VIII
Statistical Analysis
The probabihty of the persistence of a factoi VIII mhibitoi over time
was evaluated by the Kaplan Meier method (17) and the logiank lest (18) The
startmg-pomt for the life-table was the initial treatment with immune tolerance
therapy, or, m non-treated patients, the time of mhibitor delection
Results
Figure l shows the cumulative number of mhibitors regtstered m our
center smce 1966 Most of the gradual increase over time will reflect
the mcreased total number of hemophilia patients and the growth of the
catchment area of our center In 1991 and 1992, however, an mcreased
mcidence of mhibitor development occmred The clmical course of
this group of mhibitor patients was compared with the classic mhibitor
patient group (table 1)
l Classic Inhibitors (group 1)
In these 32 patients the mhibitor was first detected at a median age
of 8 3 years (ränge 1-39 years) All mhibitors were detected before
the 50th day of exposure, after treatment with cryoprecipitate, or
vanous factor VIII concentrates Thirty patients were tested because of
mcreased bleedmg problems, two were detected at routme laboratory
control
Nme patients (group l a) did not receive immune tolerance therapy
In five patients who did not receive any factor VIII therapy aftei
developmg an mhibitor, the mhibitoi levels remamed above 10 BU/ml
Three of these 5 patients died (one of an unmanageable bleedmg), the
other two patients still have mhibitor levels above 30 BU/ml Four
patients received only short-term factor VIII therapy (7 to 10 days),
with 50 U/kg body weight daily, foi hfe threatemng bleedmg episodes
or surgery Withm this penod their mhibitoi levels mcieased to over
100 BU/ml and factor VIII admimstiation had to be discontmued
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Twenty-three patients (gioup l b) leceived immune toleiance
theiapy Nineteen patienls (83%) weie tieated only with a low dose
regimen (25 U/kg body weight 3-4 times a week), which was success
ful aftei 2-28 months m all 19 patients In 2 patients immune toleiance
was not achieved even aftei additional theiapy with gammaglobulms
and cyclophosphamide (19), and factoi VIII theiapy was discontinued
after two yeais Two othei patients still receive immune tolerance
therapy
In eleven patients with mhibitoi titeis that nevei exceeded 60 BU/ml
immune tolerance was obtamed more easily, aftei 2-11 months
(median 6 months) than m the eight patients with mhibitoi levels
above 60 BU/ml 12-28 months (median 19 months) Several factor
VIII pioducts were used, without any obvious lelation between the
concentrate and the success late
2 Recent Inhibitors (group 2)
Twelve patients m whom a persistent mhibitoi developed after
June 1990 weie eligible for follow-up The median age at mhibitor
development was 22 years (1-57 yeais) Stiikmgly, pnor to mhibitoi
development, most patients had received several hundreds of exposures
to factoi VIII with vanous concentiates, before they changed to Factor
VIIICPS P After this change, it still took moie than 50 exposure days
to this paiticulai concentiate before the mhibitor became appaient m
ten of the twelve mhibitor patients
In two patients factor VIII admimstration was discontinued, and in
the othei 10 patients immune toleiance theiapy with factor VIIICPS-P
was staited, m a legimen of 25 U/kg body weight factor VIII on
altemate days This therapy was successful in only one patient, wheieas
mhibitoi levels lemamed the same 01 even incieased m mne Dosage
increases to 50 U/kg body weight factor VIII (12,20) in 4 patients with
severe clmical problems, and additional coiticosteroid admimstiation
(21) m one of them, did not have any beneficial effect In all mne
non-respondmg patients we switched to anothei concentrate, fust m
the foui patients with debihtating bleedmgs, and latei, when Factor
VIII CPS-P was taken of the maiket (Maich 1992), m the othei
five patients In all mne patients the change to anothei concentiate
resulted in a rapid deciease of the mhibitoi titei to less than l BU/ml
withm 8 months, noimal recoveiy tests, and the disappearance of
clmical bleeding Symptoms The concentiates that were used mstead
of Factor VIII CPS-P mcluded ultra-puie monoclonally punfied and
mtei mediale punfied concentrate, and pasteunsed äs well äs SD
pioducts (Factor VIII M-SD, Hemofil M-SD, Monoclate-P,
Haemate P)
In one patient immune tolerance therapy with factoi VIII CPS-P
proved to be successful This patient lesembled a classic mhibitoi smce
he had developed an mhibitoi withm 10 exposuie days at the age of
l 5 yeais
As Fig 2 shows, Inhibitors disappeared much soonei (withm one
year) m these lecently developed mhibitor patients than m classical
mhibitois (p<00001) Moieover, success was achieved m all
Inhibitors
Discussion
Previous leports have shown that the use of a particulai concentiate
(factor VIII CPS-P) can be associated with an incieased nsk of
mhibitoi development (9, 10) In this study we have shown that the
clmical course of these Inhibitors is different foi classic mhibitois, with
a rapid disappeaiance m all patients after a change of concentrate
Usually mhibitois m hemophiha patients are detected before
50 exposuie days to factoi VIII (7) In oui gioup of classic mhibi-
tois antibodies were detected at a relatively late age, 7 years (lange
1-22 yeais) This can be explamed by the fact that most Inhibitors
weie diagnosed before 1980 at that time leplacement therapy was
less ftequent than today and mhibitor measurements were not
perfoimed on a routme basis However the median age m the group
of lecent inmbitors was much higher 22 years (lange 1-57 years)
In the classic mhibitor gioup the total number of exposuie days to any
pioduct was much lowei than in the group of lecent Inhibitors
Moreover, the patients m this last group even had a highei number of
exposure days to the new concentiate Factor VIII CPS P pnoi to the
mhibitor developed
Until 1982 it was common piactice to discontmue factor VIII
theiapy once an mhibitoi had developed In our clmic immune
toleiance theiapy was staited m most mhibitor patients between 1982
and 1985 Successful immune toleiance therapy seems to be mdepen-
dent of the pioduct used, but highly dependent on the mhibitor level
(11, 12) In patients with mhibitor levels over 50 B U/l mhibitoi titers
dechned only slowly, wheieas patients with mhibitor levels over
200 BU/ml did not respond even to the most extended and comprehen
sive immune tolerance legimens (19) In sharp contrast the decrease of
the mhibitor titers in the group of lecent mhibitors was related to the
pioduct used foi immune toleiance therapy, rathei than to the mhibitoi
level Only an 18 months old patient with less than 10 days of
exposure to factor VIII seemed to behave hke a classic mhibitor It is
stnkmg that 2 patients with mhibitor levels ovei 300 BU/ml showed a
lapid fall of mhibitoi titers after the change to another concentrate It
seems hke that the mechamsm of this successful treatment was nol that
of immune toleiance, which is thought to be the lesult of anti idiotype
anlibody formation (22) A possible explanation foi the lapid declme of
mhibitor titeis is that the change of concentiate led to the removal of an
umque anügemc Stimulation aftei which the pioduction of antibodies
stopped This also has been made plausible m laboratoi y mvestigations
(23)
The cause of the antigemcity of Factor VIII CPS-P remams
unclear Its predecessoi, Factor VIII CPS was prepaied by control
led-poie silica adsoiption (24), and mitially diy heal-lrealed at 68° C
for 72 h (CPS HT) Aftei the mtroduction of Factoi VIII CPS-HT
m 1988, no mciease in mcidence of mhibitors was seen (9) In
1990 a fuither improvement m virus safety was achieved with
the mtroduction of pasteunsation (Factoi VIII CPS-P) (25) Still
pasteunsation itself does nol seem to change immunogemcity This
may be concluded ftom the fact that similar mhibitor epidemics
were not observed aftei the mtroduction of other pasteunsed products
(9) and is also suppoited by the fact thal m 5 palienls Factoi VIII
CPS-P was replaced by anolher pasteunsed product with good
lesult Thoiough analysis of the production process of Factoi VIII
CPS-P was undeitaken bul no explanation has been found Recently,
it has been shown that the pasteunsed product had a much higher
rate of factor Xa geneiation lhan the diy heat-treated, suggestive of the
presence of small amounts of activated factor VIII (26) It is not
obvious why this would lead to a highei nsk of mhibitoi develop-
ment, and moie leseaich will be necessaiy lo further clanfy the
umque event of an epedemic of mhibitois m multitiansfused hemophi-
ha patients
In summary We conclude thal the mcrease m the mcidence of
mhibitois from 1990 lo 1992 m The Netherlands aftei mtroduction of
Factoi VIII CPS-P was followed by a rapid disappearance of all
mhibitors after the patienls had switched to another concentrate
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